JWH-019 is ananalgesic chemical from thenaphthoylindole family that acts as acannabinoid agonist at both theCB1 andCB2 receptors. It is theN-hexylhomolog of the more common synthetic cannabinoid compoundJWH-018. Unlike thebutyl homologJWH-073, which is several times weaker than JWH-018, thehexyl homolog is only slightly less potent, although extending the chain one carbon longer to the heptyl homologJWH-020 results in dramatic loss of activity. These results show that the optimum side chain length for CB1 binding in the naphthoylindole series is the five-carbonpentyl chain, shorter than in the classical cannabinoids where a seven-carbonheptyl chain produces the most potent compounds. This difference is thought to reflect a slightly different binding conformation adopted by the naphthoylindole compounds as compared to the classical cannabinoids, and may be useful in characterizing the active site of the CB1 and CB2 receptors.[2][3][4]
^Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, et al. (August 2000). "Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding".Drug and Alcohol Dependence.60 (2):133–40.doi:10.1016/S0376-8716(99)00152-0.PMID10940540.
^Ashton JC, Wright JL, McPartland JM, Tyndall JD (2008). "Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists".Current Medicinal Chemistry.15 (14):1428–43.doi:10.2174/092986708784567716.PMID18537620.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived fromthe original on 1 October 2015. Retrieved1 October 2015.
